Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G/A for Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value (VRDN).
- Disclosed ownership: 3.9%.
- Date of event: 30 Sep 2025.
Commodore Capital LP - 30 Sep 2025 SCHEDULE 13G/A Report for Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value (VRDN)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- VRDN
- Shares outstanding
- 82,051,282 shares
- Disclosed Ownership
- 3,200,000 shares
- Ownership
- 3.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 17:17:25 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 11 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 3.9% ownership in Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value (VRDN) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 11 Apr 2025.
- Current filing was accepted on 14 Nov 2025, 17:17.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 3.9% | 3,200,000 | 0 | 3,200,000 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 3.9% | 3,200,000 | 0 | 3,200,000 | Michael Kramarz | Managing Partner |